Tokyo, Nov. 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063277) titled 'Test on the Application of Aza-Oxohypoxanthine (AOH) Formulation Following SKINJET Treatment' on Nov. 2.

Study Type: Interventional

Study Design: Basic Design - Factorial Randomization - Randomized Blinding - Open -no one is blinded Control - Placebo

Primary Sponsor: Institute - Mitsubishi Corporation Life Sciences Limited

Condition: Condition - Healthy Adults Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - Evaluation of the effects of AOH contained formulation on skin condition as post-treatment care following SKINJET treatment. Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - SKINJET treatment is performed three times at two-week intervals. AOH formulation is applied daily for six weeks. Interventions/Control_2 - SKINJET treatment is performed three times at two-week intervals. Apply the regular skincare product (which does not contain AOH) daily for six weeks.

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Adults aged 18 years or older, of either sex, who understand the details of the study and provide informed consent to participate. Individuals who are willing to use only the designated cosmetic products during the study period. Individuals whom the principal investigator deems eligible to participate in the study. Key exclusion criteria - Individuals who are pregnant or breastfeeding. Individuals who have previously undergone treatment involving metal plates, metal threads, or similar devices. Individuals with a metal allergy or a tendency to develop keloids. Individuals who currently have an implanted medical device, such as a pacemaker. Individuals who have undergone dental treatment involving implants, bridges, or similar devices. Individuals with allergies to medications, such as local anesthetics. Individuals who are currently taking blood-thinning medications. Individuals with a history of epilepsy, diabetes mellitus (including diabetic complications), malignant skin tumors, or autoimmune diseases. Individuals who currently have symptoms of dermatitis or herpes simplex. Individuals who have undergone aesthetic medical treatment on the face within one month prior to the start of the study. Individuals who are currently participating in another clinical trial, have participated in another clinical trial within the past three months or are likely to participate in another clinical trial during the study period. Individuals whom the principal investigator otherwise considers unsuitable for participation in the study. Target Size - 6

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2026 Year 10 Month 30 Day Anticipated trial start date - 2026 Year 11 Month 02 Day Last follow-up date - 2026 Year 12 Month 16 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072432

Disclaimer: Curated by HT Syndication.